DKSH Highlights New Approaches to HPV Early Treatment and Cervical Care for Thai Women

Amid growing awareness of women’s wellness in Thailand, DKSH Thailand has launched an initiative to break the stigma and uncertainty around cervical health and empower women with evidence-based, proactive care option. The initiative follows DKSH’s recent market introduction of innovative vaginal spray gel designed to support early management of HPV-related cervical lesions.

Bangkok, Thailand, November 27, 2025 – DKSH Business Unit Healthcare, a strategic healthcare solutions partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health, and medical device companies, recently brought healthcare professionals, wellness influencers and media representatives together in Bangkok to discuss treatment approaches and emotional burden associated with Human Papillomavirus (HPV) diagnosis.

DKSH recently introduced an innovative vaginal spray gel developed to support the early management of cervical lesions associated with HPV. The product offers women with a proactive care option, helping double HPV clearance and support regression of pre-cancerous cervical lesions^1,2  particularly during the “wait-and-see” period commonly used for low-grade cervical changes. The event is part of a broader initiative to remove the stigma that still exists around cervical health, promote lesion regression, HPV clearance, reduce future risk and raise awareness about the emotional toll of diagnosis and follow-up care.

Addressing an ongoing health concern 

Cervical cancer remains one of the most significant health concerns for women, ranking as the second most common cancer among women in Thailand. HPV is recognized as the leading cause of cervical cancer. For cases such as low-grade squamous intraepithelial lesions (LSIL) or cervical intraepithelial neoplasia grade 1 (CIN1), physicians often adopt a “wait-and-see” follow-up approach due to the high rate of spontaneous regression. However, research indicates that a proportion of HPV infections may persist^3*, up to 31% of women with high-grade cervical lesions may face progression toward cervical cancer^4Ɨ, and many experience emotional stress throughout the follow-up period⁵.

Speaking at the event, Assoc. Prof. Dr. Wichai Termrungruanglert, Chairman of the Gynecologic Oncology Committee of The Royal Thai College of Obstetricians and Gynaecologists (RTCOG), said: “While the wait-and-see approach is used for low-risk HPV and many cases resolve naturally, most women still experience fear and emotional distress throughout the follow-up period. The key is timely support that addresses both the physical and emotional aspects of their health. By empowering women with proactive care options, it can help reduce unnecessary anxiety and the fear of potential disease progression. This represents a very positive step forward, especially for women who want to be proactive and feel more in control rather than simply wait and anxiety”

Dr. Olarik Musigavong, a reproductive medicine specialist and minimally invasive gynecologic surgeon, underscored that “HPV is extremely common, with around 80% of sexually active women acquiring it at least once. While most infections clear naturally, persistent HPV can progress to cervical lesions or cancer. Yet stigma and misunderstanding often keep women from speaking openly or seeking care, leading to delayed check-ups and treatments. He stressed the need to normalize conversations about cervical health and empower women with accurate, accessible information so they can take action earlier and confidently”

During the event, women’s wellness advocates Ms. Inthipon Tamsukhin (Maxdicine) and Ms. Mondhira Piamrattanawong (Pairyinwonderland) were open about their personal experiences with HPV.

Patcharawalai Wongruksat, Senior Manager, Marketing Management, DKSH Healthcare Thailand, added: “DKSH is committed to empowering women with accurate and accessible health information, because proactive care truly begins with understanding. Our goal is to provide healthcare solutions that address not only clinical needs but also the emotional well-being of women navigating cervical health concerns. At DKSH, we aim to promote proactive care by working closely with healthcare experts to deliver reliable knowledge and ensure women have access to supportive, science-based options - helping them feel more confident, informed, and in control of their health.”

Science-backed solutions for women’s health

DKSH Business Unit Healthcare Thailand has introduced an innovative vaginal spray gel designed to support the early management of cervical lesions associated with Human Papillomavirus (HPV). Its clinically tested ingredients help double HPV clearance^1,2, support the regression of pre-cancerous cervical lesions up to 95.7%^1,2, and help restore healthy vaginal microbiota balance and natural tissue repair¹. Intended for early management -particularly low-grade cervical lesions - and suitable for at-home use under medical guidance and prescription, the product offers women a simple, science-backed option to proactively care for their cervical health, promote healing, and reduce future risk during the follow-up period.

MA code 25111866-NP (Exp.Nov2027)

*Persistent infection lasting more than two years significantly elevates the risk of severe abnormalities and cancer.
Ɨ Within 30 years, women with high-grade cervical abnormalities. 
1. Lavitola, Giada, et al. BioMed Research International 2020.1 (2020): 5476389.
2. Stentella, Patrizia, et al. Minerva Ginecologica 69.5 (2017): 425-430.
3. Zhao, Ming, et al. Iscience 27.10 (2024).
4 McCredie, Margaret RE, et al. The lancet oncology 9.5 (2008): 425-434.
5 Jentschke, M., et al. Archives of Gynecology and Obstetrics 302.3 (2020): 699-705.